Clinical efficacy of submucosal injection of triamcinolone acetonide in the treatment of type II/III interstitial cystitis/bladder pain syndrome
BMC Urology Apr 02, 2020
Jiang T, Zhou X, Chen Z, et al. - The effectiveness of submucosal injection of triamcinolone acetonide for the treatment of type II/III interstitial cystitis/bladder pain syndrome was evaluated. Researchers performed a retrospective analysis of the clinical data of type II/III interstitial cystitis/bladder pain syndrome patients treated in our department from April 2016 to August 2018, and changes in International Prostate Symptom Scores and the Pelvic Pain and Urgency/Frequency symptom scale after surgery were examined to investigate factors that may affect patient outcomes. This study included a sum of 27 female individuals and 8 male patients, with type II patients accounting for 62.9% of the sample, and the median follow-up duration was 31 months (range: 12–40 months). In both men and women with type II/III interstitial cystitis/bladder pain syndrome, study reveals that submucosal injection of triamcinolone acetonide can enhance the clinical symptoms and quality of life. The study found that triamcinolone acetonide injection can be useful in patients with an advanced age and more severe interstitial cystitis/bladder pain syndrome related symptoms.
55 lakhs+ doctors trust M3 globally
Unlimited access to original articles by experts
Secure: we never sell your data
Signing up takes less than 2 mins